BRPI0606772A2 - método para a caracterização da eficácia de um agente contra um efeito da fibrose cìstica - Google Patents

método para a caracterização da eficácia de um agente contra um efeito da fibrose cìstica

Info

Publication number
BRPI0606772A2
BRPI0606772A2 BRPI0606772-7A BRPI0606772A BRPI0606772A2 BR PI0606772 A2 BRPI0606772 A2 BR PI0606772A2 BR PI0606772 A BRPI0606772 A BR PI0606772A BR PI0606772 A2 BRPI0606772 A2 BR PI0606772A2
Authority
BR
Brazil
Prior art keywords
agent
characterizing
cystic fibrosis
population sample
effectiveness
Prior art date
Application number
BRPI0606772-7A
Other languages
English (en)
Inventor
Donald Vadevanter
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of BRPI0606772A2 publication Critical patent/BRPI0606772A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO PARA A CARACTERIZAçãO DA EFICáCIA DE UM AGENTE CONTRA UM EFEITO DA FIBROSE CìSTICA. De forma geral, o método para caracterização da eficácia de um agente que tem como alvo um defeito primário da fibrose cística compreende a medição de uma alteração no estado de infecção pulmonar em uma amostra populacional de indivíduos que receberam a administração do agente em comparação com uma amostra populacional de indivíduos de controle; em que os indivíduos na amostra populacional e na amostra populacional de controle têm o defeito primário da fibrose cística e não estão infectados antes de o agente ser administrado; em que uma alteração benéfica na presença de infecção pulmonar na amostra populacional em comparação com a amostra populacional de controle é indicativa de um efeito do tratamento; e em que o agente é desprovido de atividade antibiática intrínseca.
BRPI0606772-7A 2005-01-27 2006-01-27 método para a caracterização da eficácia de um agente contra um efeito da fibrose cìstica BRPI0606772A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64747705P 2005-01-27 2005-01-27
PCT/US2006/002949 WO2006081429A1 (en) 2005-01-27 2006-01-27 A method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect

Publications (1)

Publication Number Publication Date
BRPI0606772A2 true BRPI0606772A2 (pt) 2009-07-14

Family

ID=36168360

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606772-7A BRPI0606772A2 (pt) 2005-01-27 2006-01-27 método para a caracterização da eficácia de um agente contra um efeito da fibrose cìstica

Country Status (12)

Country Link
US (1) US7485284B2 (pt)
EP (1) EP1848993A1 (pt)
JP (1) JP2008528032A (pt)
KR (1) KR20070101356A (pt)
CN (1) CN101107520A (pt)
AU (1) AU2006207998A1 (pt)
BR (1) BRPI0606772A2 (pt)
CA (1) CA2596082A1 (pt)
IL (1) IL184882A0 (pt)
MX (1) MX2007009013A (pt)
RU (1) RU2007132123A (pt)
WO (1) WO2006081429A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2590989C2 (ru) * 2014-09-29 2016-07-10 Михаил Львович Абрамович Способ оценки эффективности и безопасности терапии при проведении клинических исследований
RU2686052C1 (ru) * 2018-10-01 2019-04-24 Андрей Владимирович Козлов Способ оценки активности инфекционного процесса, вызванного неферментирующими грамотрицательными бактериями в бронхолегочной системе у пациентов с муковисцидозом
CN113345600B (zh) * 2021-05-06 2024-02-27 中国食品药品检定研究院 一种抗感染药物注射剂的有效性评价方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031706A1 (en) * 1997-01-15 1998-07-23 Johns Hopkins University METHODS OF TREATING LUNG INFECTIONS WITH HUMAN TRACHEAL ANTIMICROBIAL PEPTIDE (hTAP)
BR9915218A (pt) * 1998-11-18 2001-07-31 Childrens Hosp Medical Center Composição proteìna de fusão, lisozima recombinante e método de profilaxia ou tratamento terapêutico de infecção bacteriana em mamìfero
CN1606446A (zh) * 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法

Also Published As

Publication number Publication date
US20060177375A1 (en) 2006-08-10
EP1848993A1 (en) 2007-10-31
IL184882A0 (en) 2007-12-03
CA2596082A1 (en) 2006-08-03
RU2007132123A (ru) 2009-03-10
JP2008528032A (ja) 2008-07-31
CN101107520A (zh) 2008-01-16
MX2007009013A (es) 2007-09-14
WO2006081429A1 (en) 2006-08-03
KR20070101356A (ko) 2007-10-16
AU2006207998A1 (en) 2006-08-03
US7485284B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
Derouiche Oxidative stress associated with SARS-Cov-2 (COVID-19) increases the severity of the lung disease-a systematic review
Zou et al. Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments
Sanguinetti N-acetylcysteine in COPD: why, how, and when?
Santus et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine
Clunes et al. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder
Hasan et al. Inhibition of major virulence pathways of Streptococcus mutans by quercitrin and deoxynojirimycin: a synergistic approach of infection control
Eccles et al. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial
Heijerman Infection and inflammation in cystic fibrosis: a short review
Cazzola et al. Thiol-based drugs in pulmonary medicine: much more than mucolytics
Shepherd et al. Pseudomonas aeruginosa adapts to octenidine in the laboratory and a simulated clinical setting, leading to increased tolerance to chlorhexidine and other biocides
Bensel et al. Lactate in cystic fibrosis sputum
BRPI0512146A (pt) métodos para o tratamento de uma infecção endobrÈnquica em um paciente, e de um paciente com fibrose cìstica, sofrendo de uma infecção endobrÈnquica
Li et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms
Florescu et al. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis
Rowe et al. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis
García et al. Treatment of non-cystic fibrosis bronchiectasis
Poole et al. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents
AU2020298870A1 (en) Therapeutic uses of oxidising hypotonic acid solutions
BRPI0606772A2 (pt) método para a caracterização da eficácia de um agente contra um efeito da fibrose cìstica
Bermejo-Martin et al. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains
Wang et al. Glycyrrhizin mitigates acute lung injury by inhibiting the NLRP3 inflammasome in vitro and in vivo
Li et al. Naringenin alleviates myocardial ischemia reperfusion injury by enhancing the myocardial miR-126-PI3K/AKT axis in streptozotocin-induced diabetic rats
Bayindir et al. Synergic viral-bacterial co-infection in catalase-deficient COVID-19 patients causes suppressed innate immunity and lung damages due to detrimental elevation of hydrogen peroxide concentration
Cho et al. Unified Airway—Cystic Fibrosis
Thellin et al. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]